Early biochemical outcomes following neoadjuvant/adjuvant relugolix with stereotactic body radiation therapy for intermediate to high risk prostate cancer

INTRODUCTION: Injectable GnRH receptor agonists have been shown to improve cancer control when combined with radiotherapy. Prostate SBRT offers an abbreviated treatment course with comparable efficacy to conventionally fractionated radiotherapy. Relugolix is a new oral GnRH receptor antagonist which...

Descripción completa

Detalles Bibliográficos
Autores principales: Gallagher, Lindsey, Xiao, Jerry, Hsueh, Jessica, Shah, Sarthak, Danner, Malika, Zwart, Alan, Ayoob, Marilyn, Yung, Thomas, Simpson, Tiffany, Fallick, Mark, Kumar, Deepak, Leger, Paul, Dawson, Nancy A., Suy, Simeng, Collins, Sean P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10616590/
https://www.ncbi.nlm.nih.gov/pubmed/37916156
http://dx.doi.org/10.3389/fonc.2023.1289249

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10616590/
https://www.ncbi.nlm.nih.gov/pubmed/37916156
http://dx.doi.org/10.3389/fonc.2023.1289249

Ejemplares similares